Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA

Journal of Immunological Methods

Volumn 226, Issue 1-2, 1999, Pages 169-177

  Hornig, Carsten ^a   Behn, Tanja ^a   Bartsch, Wolfgang ^b   Yayon, Avner ^c   Weich, Herbert A ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b City Hospital   (Germany)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Angiogenesis; ELISA; Soluble VEGFR 1; VEGF

Indexed keywords

GENE PRODUCT; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR;

AMNIOCENTESIS; AMNION FLUID; ANGIOGENESIS; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; PRIORITY JOURNAL; RNA SPLICING;

ANIMALS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; CROSS REACTIONS; CULTURE MEDIA; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIGANDS; MICE; PROTO-ONCOGENE PROTEINS; RABBITS; RECEPTOR PROTEIN-TYROSINE KINASES; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 0032795396     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(99)00065-4     Document Type: Article

References (18)

1. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A.F., Alitalo K., Stacker S.A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinase VEGF receptor 2 (FLK) and VEGF receptor 3 (Flt-4). Proc. Natl. Acad. Sci. U.S.A. 95(2):1998;548-553.
2. Banks R.E., Forbes M.A., Searles J., Pappin D., Canas B., Rahman D., Kaufmann S., Walters C.E., Jackson A., Eves P., Linton G., Keen J., Walker J.J., Selby P.J. Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, FLT-1. Mol. Hum. Reprod. 4:1998;377-386.
3. Barleon B., Hauser S., Schöllmann C., Weindel K., Marmé D., Yayon A., Weich H.A. Differential and tissue specific expression of flt and KDR receptors in vascular endothelial cells. J. Cell. Biochem. 54:1994;56-66.
4. Barleon L.et al. VEGF upregulated its receptor FLT-1 and a soluble variant in human vascular EC. Cancer Res. 57:1997;5421-5425.
5. Clauss M., Weich H., Breier G., Knies U., Röckl W., Waltenberger J., Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. J. Biol. Chem. 271:1996;17629-17634.
6. Fernandez Botran R., Vitetta E.S. Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J. Exp. Med. 174:1991;673-681.
7. Hanneken A., Ying W., Ling N., Baird A. Identification of soluble forms of the FGF receptor in blood. Proc. Natl. Acad. Sci. U.S.A. 91:1994;9170-9174.
8. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15:1996;290-298.
9. Kendall R.L., Thomas K.A. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. U.S.A. 90:1993;10705-10709.
10. Kendall R.L., Wang G., Thomas K.A. Identification of a natural soluble form of vascular endothelial growth factor receptor, Flt-1 and heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226:1996;324-328.
11. Kondo K., Kiratsuka S., Subbalakshmi E., Matsushime H., Shibuya M. Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. Gene. 208:1998;297-305.
12. Novick D., Engelmann H., Wallach D., Rubinstein M. Soluble cytokine receptors are present in normal urine. J. Exp. Med. 166:1989;1409-1414.
13. Olofsson B., Korpelainen E., Pepper M.S., Mandriota S.J., Aase K., Kumar V., Gunji Y., Jeltsch M.M., Shibuya M., Eriksson U. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 95(20):1998;11709-11714.
14. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
15. Röckl W., Hecht D., Sztajer H., Waltenberger J., Yayon A., Weich H.A. Differential binding characteristics and cellular inhibition by soluble forms of KDR and FLT-1. J. Exp. Cell Res. 241:1998;161-170.
16. Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 5:1990;519-524.
17. 125I -VEGF binding sites J. Am. Soc. Nephrol. 9(6):1998;1032-1044.
18. Terman B., Khandke L., Dougher-Vermazan M., Maglione D., Lassam N.J., Gospodarowicz D., Persico M.G., Bohlen P., Eisinger M. VEGF receptor subtypes KDR and FLT-1 show different sensitivities to heparin and placenta growth factor. Growth Factors. 11:1994;187-195.